Krystal Biotech (KRYS) Bank of America Global Healthcare Conference 2026 summary

Financial performance and business model

• Achieved 11-12 consecutive quarters of positive EPS and gross margins in the 90-95% range, reflecting a sustainable business model.

• Global launch of main asset has exceeded expectations, with strong performance in France, Germany, and Japan, and launches in Italy and Spain planned for the second half of the year.

• U.S. market penetration is at about 60% of identified patients, with ongoing growth expected as the company targets a broader prevalence.

• Cost structure remains stable, with small teams per country and operating expenses for 2026 projected to be similar to last year, even as new assets enter the clinic.

• Most U.S. payer agreements have moved beyond the initial $900K cap, simplifying reimbursement.

Global launch and pricing dynamics

• Ex-U.S. launches are progressing well, with Japan, Germany, and France showing strong patient uptake and positive pricing outcomes.

• Italy and Spain launches are accelerated to the second half of the year, with high physician awareness and no accrual-based pricing; prices will be set before launch.

• Revenue recognition in Europe is transitioning from rough patient number proxies to direct revenue reporting by geography.

• Ongoing pricing negotiations in Germany and Italy, with expectations set by positive outcomes in Japan.

• Most Favored Nation (MFN) policy considerations are factored into ex-U.S. pricing strategies to protect long-term U.S. business.

Pipeline and clinical development

• Ocular DEB program (KB803) pivotal trial fully enrolled, leveraging a natural history study for robust patient-reported outcomes; data expected in 4Q.

• The same vector and mechanism as the main asset is used, with endpoints focused on symptom reduction and quality of life improvements.

• Significant overlap between patients in the ocular DEB program and those already on the main asset, facilitating commercial synergies.

• Neurotrophic keratitis (NK) program expanded to 60 patients with daily self-administration; primary endpoint is independent reader-assessed lesion healing at 8 weeks.

• Cystic fibrosis (CF) program has demonstrated molecular correction and is moving to a repeat-dose safety study, with pivotal trial design discussions ongoing and expected to finalize by year-end.